A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
← catalyst calendarNCT07221500 · readout ≤ 529 d
Sponsored by Nurix Therapeutics, Inc. (industry) · NRIX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
37
Countries
France, Italy, Poland +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-15 | actual | When the study began enrolling |
| Primary completion | Jan 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
Intervention
- Drug: NX-5948 — also filed as Bexobrutideg
Primary outcome
what the primary-completion date above is the date OFObjective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC)
measured Up to approximately 5 years
Permalink · NRIX's whole pipeline · Catalyst calendar · Every registered study · What changed